- About us
- About Vaccines
- Media centre
- EU initiatives
Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.
The article titled Innovation Partnership for a Roadmap on Vaccines in Europe (IPROVE): A vision for the vaccines of tomorrow was published in the scientific journal “Vaccine” in February 2018. Access the article here.
Vaccines Europe conducted an internal prioritisation exercise of the roadmap to select the main R&D priorities of the IPROVE recommendations and this document can be accessed here.
In a time where Europe is facing mobility of citizens, vaccination policies need to utilize technological advancements to increased access to health records within the Member States and across Europe. Health systems are moving towards e-Health, (i.e. tools and services using information and communication technologies).
Vaccines Europe developed a paper outlining the Immunisation Information System (IIS) capabilities, current challenges with IIS and proposals for a way forward. You can access the paper here.
The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today responded to the European Council approving terms of the transition period agreed between the UK Government and EU.
Today’s agreement on a transition period is welcome news for Europe’s Life Sciences industry. While expecting a deal on the withdrawal agreement as soon as possible, this gives companies more certainty about the time they will have to prepare for the UK’s departure from the EU.
At the current status of negotiations, we continue to advise our members to prepare for every scenario and ensure that they have the right plans in place so that patients across Europe and in the UK continue to access the medicines they need.
However, as Article 50 negotiations progress to the next phase, clarity over the UK and Europe’s future relationship on the regulation, trade and supply of medicines needs to be provided as soon as possible. Alongside Europe’s patient groups and healthcare organisations, Europe’s Life Sciences industry will continue to advocate that the best outcome for patients is an agreement for the EU and the UK to continue to cooperate on medicines.